The 36-month beta value for APLS is at 0.67. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 4 rating it as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for APLS is 103.36M, and currently, shorts hold a 24.22% of that float. The average trading volume for APLS on June 20, 2025 was 2.64M shares.
APLS) stock’s latest price update
The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by 0.00 when compared to previous closing price of 17.76, but the company has seen a -7.84% decline in its stock price over the last five trading sessions. zacks.com reported 2025-06-06 that Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What’s next for the stock?
APLS’s Market Performance
APLS’s stock has fallen by -7.84% in the past week, with a monthly rise of 0.51% and a quarterly drop of -28.42%. The volatility ratio for the week is 1.39% while the volatility levels for the last 30 days are 3.75% for Apellis Pharmaceuticals Inc The simple moving average for the past 20 days is -2.86% for APLS’s stock, with a -33.62% simple moving average for the past 200 days.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Raymond James repeating the rating for APLS by listing it as a “Outperform.” The predicted price for APLS in the upcoming period, according to Raymond James is $52 based on the research report published on May 09, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see APLS reach a price target of $23. The rating they have provided for APLS stocks is “Neutral” according to the report published on May 09th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to APLS, setting the target price at $44 in the report published on April 29th of the current year.
APLS Trading at -2.87% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.18% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Watson David O., who sale 5,000 shares at the price of $18.77 back on Jun 16 ’25. After this action, Watson David O. now owns 133,730 shares of Apellis Pharmaceuticals Inc, valued at $93,850 using the latest closing price.
Watson David O., the Officer of Apellis Pharmaceuticals Inc, proposed sale 5,000 shares at $18.77 during a trade that took place back on Jun 16 ’25, which means that Watson David O. is holding shares at $93,850 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.24 for the present operating margin
- 0.83 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.29. The total capital return value is set at -0.3. Equity return is now at value -103.82, with -27.29 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.74 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 2.86. The interest coverage ratio of the stock is -4.19.
Currently, EBITDA for the company is -154.53 million with net debt to EBITDA at -0.63. When we switch over and look at the enterprise to sales, we see a ratio of 3.02. The receivables turnover for the company is 3.17for trailing twelve months and the total asset turnover is 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.08.
Conclusion
In conclusion, Apellis Pharmaceuticals Inc (APLS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
